N
Novanta Inc.
NOVT · Technology
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Novanta Sells the Invisible Parts — At a Very Visible Price
The market is pricing Novanta as if the surgical robotics OEM aftermarket and upgrade cycle already converts at scale and AI hardware drilling becomes a major revenue pillar — in other words, every bull scenario is already in the multiple, leaving no room to be rewarded for being right.
Flowly Score
Apr 16 Close
-64%$125.90
Fair Value
$45.00
45
Below Averageat $125.90
Business Strength7/10
The switching cost moat is structurally real — FDA-embedded design-ins don't get repriced, they get renewed — but ROIC drifting toward and below cost of capital over three years reveals that the acquisition engine is deploying capital faster than it earns returns on it, which is the central tension between a quality business and a quality compounder.
Financial Resilience7/10
OCF beating net income every single year for five years is the hallmark of genuine earnings quality, not accounting theater, and the asset-light CapEx profile leaves most cash genuinely free. The $600M+ November equity raise to fund the M&A pipeline introduces fresh dilution and leverage optionality simultaneously — the balance sheet looks fine today but will look very different after the next deal closes.
Growth & Trajectory7/10
A 25% bookings surge with all four business units simultaneously in positive book-to-bill territory for the first time since 2022 is not noise — it's a demand signal that reads as genuine recovery, not channel restocking. The AI GPU board drilling opportunity and humanoid robotics design-wins are real optionality layers on top of a surgical robotics adoption curve that is still in its first innings globally.
Valuation2/10at $127.26
At nearly 90x free cash flow on a depressed FCF base that the bulls insist is cyclically trough, the stock requires a decade of flawless execution just to approach fair value — the optimistic DCF scenario still implies a stock price roughly half of where the market is trading it today. This is a business worth admiring at a different price, not at this one.
Risk4/10
Three risks compound each other uncomfortably: a CEO who chairs his own oversight board approving serial acquisitions without independent scrutiny; laser and photonics exports sitting squarely in the path of tightening US-China technology controls; and a valuation that provides zero cushion for any of these risks to materialize. The moat is real, but there is no margin of safety to absorb a stumble.
Novanta is precisely the kind of business a long-term investor should want to own: engineered invisibility inside mission-critical medical systems, pricing power confirmed by years of unmoved gross margins, and a position at the intersection of surgical robotics, AI hardware, and precision motion that benefits from platform proliferation rather than platform concentration. The problem is not the business — it is the transaction. At nearly 90x free cash flow on a year where cash generation compressed dramatically, you are paying for a version of Novanta that does not yet exist: one where robotics design-wins convert to volume, GPU board drilling scales to meaningful revenue, and the serial acquisition machine finally earns returns above its cost of capital. That is a lot of ifs baked into one price. The direction of travel is genuinely exciting. Bookings accelerating across all four business units simultaneously suggests 2025 was a cyclical trough, not a structural break, and the embedded aftermarket in an aging surgical robot installed base is still underappreciated by analysts fixated on new unit shipments. If humanoid robotics platforms standardize on Novanta's encoder and servo drive architecture — and early design-in signals suggest this is possible — the addressable market expands by an order of magnitude from today's numbers. The AI GPU drilling capability is an existing competency catching a new secular wave, not a bet-the-company pivot. The single biggest concrete risk is not competition or macro: it is vertical integration by a major OEM customer. If a tier-1 surgical robotics platform decides to bring precision motion or laser scanning in-house — and these are exactly the kinds of engineering capabilities large medtech players covet — the switching cost moat inverts. Novanta cannot easily replace a platform design-in the way a software company replaces a churned subscription. One lost platform relationship would remove years of embedded recurring revenue while the capital base stays fully loaded, and the CEO-chairman governance structure provides limited assurance that such concentration risk is being independently scrutinized.